Immune Design recruits former Elan exec

Former Elan president Carlos Paya has signed on as Immune Design's new CEO. The Seattle-based vaccine developer, which was founded in 2008, is developing therapeutic vaccines for the treatment of infectious and malignant disease. Xconomy reports that the company has already raised $50 million in venture capital and inked a partnership deal with AstraZeneca's Medimmune. Report

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.